| Management target | Revenue FY26 |
|---|
| Revenue growth | ~$1.25B revenue achieved as of March 2026. |
|---|---|
| Margins | Focus on uniform quality and significant capacity for batch sizes. |
| Demand visibility | Strong, exporting to more than 100 countries globally. |
| Management confidence | Confident, highlighting world-leader status in multiple API segments. |
Growth
Strong positioning with leadership in 10 of 28 APIs and strategic partnerships with 12 of Top 20 Big Pharma.
Outlook
Targeting growth through generic API leadership and expanded nutraceutical solutions as of March 2026.
Risks
Potential margin pressure if generic API pricing softens or custom synthesis project timelines shift.
Last quarter's promises, checked
Delivered
- Guided double-digit revenue growth → delivered 14% growth (₹9,712cr to ₹11,067cr) (= BEAT)
- Targeted Unit 3 operationalization → delivered steady production increase and GMP space freeing (= BEAT)
- Maintain supply reliability despite logistics crisis → delivered zero production stoppages (= BEAT)
Partly delivered
- Kakinada expansion (₹1,500cr) → delivered ₹600cr capitalized to date (= PARTIAL)
- Peptide business validation → delivered several fragments validated, commercialization pending customer approval (= PARTIAL)
Missed
- Historical margin levels (37-38%) → delivered ~32% (= MISS)
Earnings Call Transcript filed with NSE, NSE: DIVISLAB. Summary written with AI assistance from the document.
Divi's Laboratories Ltd: key numbers
- Share price
- ₹9,619.50
- Market cap
- ₹2,55,368 Cr
- Revenue (annual)
- ₹10,560 Cr
- Net profit (annual)
- ₹2,568 Cr
- P/E (TTM)
- 87.3×Sector 50.4×
- Promoter holding
- 51.88%+0.00% QoQ
- FII holding
- 20.19%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Divi's Laboratories Ltd
All →Divi's Laboratories Other Announcement
An immediate relative of a Divis Laboratories promoter bought equity shares worth ₹0.58 Crore through a market purchase.
- Value
- ₹0.58 Cr
Divi's Laboratories Other Announcement
Designated Person PRASAD Y.T.S. disclosed the release of two share pledges involving 2,734 equity shares. The combined transaction value of the released pledges is Rs. 2.56 Crore.
- Value
- ₹2.56 Cr
Divi's Laboratories Other Announcement
Designated person PRASAD Y.T.S. sold 6,234 equity shares of Divis Laboratories Ltd for ₹5.84 Crore via market sale.
- Value
- ₹5.84 Cr
Divi's Laboratories Promoter Selling: ₹0.19 Cr
K. Sridevi, an immediate relative, sold 200 equity shares of Divi's Laboratories Ltd via a market sale worth ₹0.19 Crore.
- Value
- ₹0.19 Cr
Divi's Laboratories Other Announcement
K. Sridevi, an immediate relative, sold 200 equity shares of Divi's Laboratories Ltd in a market transaction valued at ₹18.56 Lakh.
- Value
- ₹0.19 Cr
Divi's Laboratories Q1 FY27 Results: Net Profit ₹902 Cr, Up 65.5% YoY
Divi's Laboratories Ltd reported revenue from operations of ₹3,080 Cr (+27.8% YoY) and net profit of ₹902 Cr (+65.5% YoY) for Q1 FY27.
- Key figure
- Net profit ₹902 Cr · +65.5% YoY